 |
|
Combination Therapy With Hormone Replacement and Alendronate for Prevention of Bone Loss in Elderly Women
A Randomized Controlled Trial
Susan L. Greenspan, MD;
Neil M. Resnick, MD;
Robert A. Parker, ScD
JAMA. 2003;289:2525-2533.
Context Therapy with individual antiresorptive agents has been shown to be effective for prevention and treatment of postmenopausal osteoporosis, but whether combination antiresorptive therapy with hormones and bisphosphonates is safe or efficacious or how these agents compare in elderly women is unknown.
Objective To determine whether hormone replacement and the bisphosphonate alendronate sodium in combination are efficacious and safe, and how they compare with monotherapy in community-dwelling elderly women.
Design Randomized, double-blind, placebo-controlled, clinical trial.
Setting and Participants Five hundred seventy-three community-dwelling women age 65 years or older were screened: 485 completed screening and 373 (aged 65 to 90 years) were randomized following a 3-month, open-label, run-in phase with hormone replacement and alendronate placebo. The trial was conducted at a single academic US medical center from January 1996 to May 2001.
Interventions Participants were randomly assigned in a 2 x 2 factorial design to receive hormone replacement (conjugated equine estrogen, 0.625 mg/d, with or without medroxyprogesterone, 2.5 mg/d) and alendronate, 10 mg daily, both agents, or neither. All participants received calcium and vitamin D supplements.
Main Outcome Measures Annualized change in bone mineral density of the hip and spine and occurrence of adverse events.
Results Bone mineral density at 3 years was significantly greater at all femoral and vertebral sites in women treated with combination therapy than with monotherapy, with mean (SD) increases of 5.9% (3.8) at the total hip, 10.4% (5.4) at the posteroanterior lumbar spine, and 11.8% (6.8) at the lateral lumbar spine. Mean (SD) increases in bone mass at the hip in women treated with alendronate alone were significantly greater than in those treated with hormone replacement therapy alone (4.2% [3.8] vs 3.0% [4.9]; P<.05, respectively), and alendronate resulted in more responders to therapy. All therapies were well tolerated and participant retention was 90% at 3 years.
Conclusions Combination therapy with hormone replacement and alendronate was efficacious and well tolerated in this cohort. Alendronate was superior to hormone replacement, and combination therapy was superior to either therapy alone. Combination therapy may represent an option for women with more severe disease or for those who have failed to achieve an adequate response to monotherapy.
Author Affiliations: Division of Endocrinology and Metabolism (Dr Greenspan) and Division of Geriatric Medicine (Drs Greenspan and Resnick), University of Pittsburgh Medical Center, Pittsburgh, Pa; and Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Mass (Dr Parker).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults
MacLaughlin and Raehl
Am J Health Syst Pharm 2008;65:343-357.
FULL TEXT
Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis
MacLean et al.
ANN INTERN MED 2008;148:197-213.
ABSTRACT
| FULL TEXT
Review of Postmenopausal Osteoporosis Pharmacotherapy
Mayes
Nutr Clin Pract 2007;22:276-285.
ABSTRACT
| FULL TEXT
Bisphosphonate Therapy: To Stop or Not to Stop?
McClung
IBMS BoneKEy 2007;4:78-82.
FULL TEXT
Postmenopausal Osteoporosis
Rosen
NEJM 2005;353:595-603.
FULL TEXT
Vitamin D Supplementation in Older Women
Greenspan et al.
J. Gerontol. A Biol. Sci. Med. Sci. 2005;60:754-759.
ABSTRACT
| FULL TEXT
Early Changes in Biochemical Markers of Bone Turnover Are Associated with Long-Term Changes in Bone Mineral Density in Elderly Women on Alendronate, Hormone Replacement Therapy, or Combination Therapy: A Three-Year, Double-Blind, Placebo-Controlled, Randomized Clinical Trial
Greenspan et al.
J. Clin. Endocrinol. Metab. 2005;90:2762-2767.
ABSTRACT
| FULL TEXT
Osteoporosis
Obstet Gynecol 2004;104:66S-76S.
FULL TEXT
ABSTRACTS
Obstet Gynecol 2003;102:637-640.
FULL TEXT
Combining Alendronate and Hormone Therapy in Elderly Women
JWatch Gastroenterology 2003;2003:7-7.
FULL TEXT
Combining Alendronate and Hormone Therapy in Elderly Women
JWatch General 2003;2003:4-4.
FULL TEXT
|
